Brief: Arch Biopartners Forms New Subsidiary To Pursue A Phase I Trial In Australia For Metablok (LSALT Peptide)
11/12/2018 13:31
Dec 11 (Reuters) -
* ARCH BIOPARTNERS FORMS NEW SUBSIDIARY TO PURSUE A PHASE I
TRIAL
IN AUSTRALIA FOR METABLOK (LSALT PEPTIDE)
* ARCH BIOPARTNERS INC - STARTED HUMAN TRIAL APPLICATION
PROCESS
WITH ALFRED HEALTH HUMAN RESEARCH ETHICS COMMITTEE
* ARCH BIOPARTNERS - FORMED ARCH CLINICAL PTY LTD, A UNIT IN
AUSTRALIA, TO PURSUE A PHASE I TRIAL IN AUSTRALIA FOR METABLOK
(LSALT PEPTIDE)
* ARCH BIOPARTNERS - DRAFT APPLICATION ACCEPTED FOR
REGISTRATION
ON DEC 10, 2018 & TO BE FOLLOWED BY FULL SUBMISSION & REVIEW IN
EARLY JANUARY 2019
* ARCH BIOPARTNERS INC - DECISION REGARDING TRIAL APPROVAL
IS
EXPECTED BEFORE FEBRUARY 2019
Source text for Eikon: ID:nGNXbh7CrD
Further company coverage: ARCH.V
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide